26Jun, 2023 CereVasc & LianMedical Announce Corporate PartnershipAdmin2023-11-06T22:31:47+00:00June 26th, 2023|Press Release|Read More
14Jun, 2023 CereVasc’s Minimally Invasive Central Nervous System Therapy Delivery System Receives Outstanding Presentation Award at American Society of Gene & Cell Therapy Annual MeetingAdmin2023-11-06T22:29:02+00:00June 14th, 2023|Press Release|Read More
04May, 2023 CereVasc to Present Data on its Minimally Invasive CNS Delivery System at Upcoming American Society of Gene and Cell Therapy Annual MeetingAdmin2023-11-06T22:08:22+00:00May 4th, 2023|Press Release|Read More
28Mar, 2023 CereVasc Appoints Dr. Adel Malek Chief Medical OfficerAdmin2023-11-06T22:03:27+00:00March 28th, 2023|Press Release|Read More
21Nov, 2022 Tufts Medical Center Neurosurgeons and CereVasc Co-founders Honored by the Society of Vascular and Interventional Neurology for Innovation in Hydrocephalus TreatmentAdmin2023-11-06T21:59:07+00:00November 21st, 2022|Press Release|Read More
29Aug, 2022 CereVasc Announces First Patient Treated in U.S. Pilot Trial Evaluating the eShunt System in Patients with Normal Pressure HydrocephalusAdmin2023-11-06T21:52:45+00:00August 29th, 2022|Press Release|Read More
09Aug, 2022 CereVasc Announces FDA Approval of Second IDE Study of the eShunt® SystemAdmin2023-11-06T21:48:30+00:00August 9th, 2022|Press Release|Read More
25Apr, 2022 First patient treated in CereVasc® clinical trial of eShunt® System for Normal Pressure HydrocephalusAdmin2023-11-06T21:37:10+00:00April 25th, 2022|Press Release|Read More
08Feb, 2022 CereVasc Receives FDA IDE Approval to Begin Initial Clinical Study of the eShunt® System for Patients with Normal Pressure HydrocephalusAdmin2023-11-06T21:21:09+00:00February 8th, 2022|Press Release|Read More
07Dec, 2021 CereVasc Announces Publication of First-in-Human Case Report of its eShunt System for the Treatment of Communicating HydrocephalusAdmin2023-11-06T21:13:31+00:00December 7th, 2021|Press Release|Read More
